Transcode Therapeutics Files 2024 10-K
Ticker: RNAZ · Form: 10-K · Filed: Apr 15, 2025 · CIK: 1829635
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Transcode Therapeutics filed its 2024 10-K. Financials for FY24 are out.
AI Summary
Transcode Therapeutics, Inc. filed its 2024 10-K on April 15, 2025, reporting its financial position as of December 31, 2024. The company, based in Boston, MA, operates in the pharmaceutical preparations sector. Key financial details and operational aspects for the fiscal year ending December 31, 2024, are presented in this comprehensive filing.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Transcode Therapeutics' financial health and operational performance for the fiscal year 2024, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Transcode Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the reporting period for financial statements.)
- 001-40363 — SEC File Number (Unique identifier for the company's filings with the SEC.)
- 25840076 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-04-15 (date) — Filing date
- Boston, MA (location) — Company headquarters
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary business of Transcode Therapeutics, Inc.?
Transcode Therapeutics, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
When did Transcode Therapeutics, Inc. file its 10-K report?
Transcode Therapeutics, Inc. filed its 10-K report on April 15, 2025.
What period does this 10-K filing cover?
This 10-K filing covers the fiscal year ending December 31, 2024.
Where is Transcode Therapeutics, Inc. headquartered?
Transcode Therapeutics, Inc. is headquartered in Boston, MA.
What is the SEC file number for Transcode Therapeutics, Inc.?
The SEC file number for Transcode Therapeutics, Inc. is 001-40363.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 15, 2025 regarding Transcode Therapeutics, Inc. (RNAZ).